Elevated Liver Enzymes After 40: What a Slightly High ALT Really Means

The line on the printout is easy to miss. Alanine aminotransferase, 46. The reference range beside it reads 10 to 55, so nothing is flagged, nothing is bolded, and the appointment moves on to blood pressure. Three years ago the same number was 24. Nobody mentions the drift, because by the laboratory's own definition nothing is wrong.

Elevated liver enzymes after 40 are among the most common findings in routine bloodwork and among the most reliably misread. A single high value often means very little on its own. But the direction that number travels across several years carries real information about how your liver is handling the metabolic load of midlife, and the reference ranges most of us are measured against were built on populations that quietly included a great many people with undiagnosed fatty liver.

What ALT and AST Actually Measure

Alanine aminotransferase and aspartate aminotransferase are enzymes that work inside cells, shuttling nitrogen between amino acids and the molecules that feed energy metabolism. They are not meant to be circulating in any quantity. When liver cells are stressed, inflamed, or dying, their membranes become leaky and these enzymes spill into the bloodstream. What the blood test reports, then, is not liver function. It is evidence of cell turnover and membrane integrity.

That distinction matters more than most people realise. A liver can be substantially fatty, inflamed, or scarred while both enzymes sit comfortably in range, because the test measures leakage rather than architecture. A normal ALT is not a clean bill of health. Equally, a brisk rise can follow something entirely benign, including an unusually hard leg session two days before the draw.

ALT is the more liver-specific of the pair. AST is abundant in skeletal muscle, heart, and red blood cells, so an isolated AST elevation frequently has nothing to do with the liver at all. The relationship between the two is one of the first things a clinician reads. Mild elevations with ALT running above AST fit the pattern usually associated with metabolic fatty liver, while AST sitting higher than ALT raises a different set of questions. The American College of Gastroenterology guideline on abnormal liver chemistries sets out how that pattern recognition should drive the rest of the investigation [1].

Why "Within Normal Limits" May Not Mean Normal

Here is the uncomfortable part. Laboratory reference intervals are statistical descriptions of a reference population, not statements about health. If the people used to define normal were themselves carrying a high burden of undetected liver disease, the printed ceiling drifts upward along with them.

A landmark analysis of nearly 7,000 prospective blood donors tested exactly that idea. When the investigators excluded everyone with markers of viral hepatitis, and then also excluded those with a raised body mass index or abnormal lipids and glucose, the upper limit of the healthy range collapsed to roughly 30 units per litre for men and 19 for women [2]. Many commercial labs still print ceilings closer to 40 or 55. The ACG guideline subsequently recommended thresholds in the region of 29 to 33 for men and 19 to 25 for women as the point at which further evaluation becomes reasonable [1].

Read against those numbers, an ALT of 46 is not a rounding error. It is a signal that has been sitting in plain sight, unflagged, because the range printed next to it was generous.

What Elevated Liver Enzymes After 40 Usually Point To

The single most common explanation in adults past 40 is metabolic fatty liver disease. A systematic review pooling global data placed the prevalence of nonalcoholic fatty liver disease at roughly 30 percent of the world's adult population, concentrated in middle age and climbing steadily across recent decades [3]. In an ordinary primary care population, that makes fatty liver the leading hypothesis for a mildly raised ALT long before anything exotic enters the conversation.

It is far from the only candidate. Alcohol remains a frequent contributor, and the threshold at which it starts to register on bloodwork is lower than most people assume. Medications matter too: statins, some antibiotics, high-dose acetaminophen, and a surprising number of unregulated herbal and bodybuilding supplements all show up in hepatology clinics. Thyroid disease, celiac disease, chronic viral hepatitis, hereditary haemochromatosis, and autoimmune hepatitis each account for a slice of cases, which is why a structured workup rather than a shrug is the appropriate response [1].

Two practical notes. Strenuous exercise can raise both enzymes for days, so a draw taken the morning after a hard session may not represent your baseline. And one abnormal result deserves a repeat before it earns a label. The useful unit of measurement here is the trend across two or three tests, not a single morning's snapshot.

The Oxidative Stress Layer Behind a Rising ALT

When fat accumulates inside liver cells, the mitochondria that process it are asked to work at an intensity they were not designed to sustain. The byproduct is a steady output of reactive oxygen species, and the cell's antioxidant systems have to absorb that load. Research into how a quiet fatty liver progresses to an inflamed one keeps returning to this point. A review in Free Radical Biology and Medicine put the mechanism plainly:

"The consequent increased generation of reactive oxygen species (ROS) and reactive aldehydic derivatives causes oxidative stress and cell death, via ATP, NAD, and glutathione depletion." [4]

Glutathione is the molecule doing most of the quiet work in that sentence. It is the liver's principal intracellular antioxidant and the cofactor for the detoxification enzymes that neutralise both metabolic byproducts and ingested compounds. The pool held inside liver mitochondria appears to be particularly consequential, with researchers describing it as something close to a survival switch for the hepatocyte [5].

Age complicates this. Work at Baylor College of Medicine found that older adults had markedly lower red blood cell glutathione than younger controls, and that the deficit came from reduced synthesis rather than faster consumption. Supplying the two rate-limiting amino acid precursors, cysteine and glycine, restored synthesis and lowered markers of oxidative stress within two weeks [6]. So the same decades that tend to add visceral fat and liver fat also tend to reduce the antioxidant capacity available to deal with them.

What the Glutathione Research Actually Shows

The most directly relevant human study is small but interesting. A Japanese multicentre pilot gave 300 mg of oral glutathione daily for four months to patients with nonalcoholic fatty liver disease. ALT fell significantly across the group, and among the participants whose ALT responded, a measure of liver fat content declined as well [7]. The authors were appropriately careful, and so should we be: this was open label and single arm, with no placebo group, in 34 people. It generates a hypothesis worth testing properly rather than settling anything.

A randomised controlled trial in European Journal of Nutrition addressed a different question, which is whether oral glutathione reaches the tissues at all. Over six months, supplementation raised body stores of glutathione in a dose-dependent and time-dependent fashion, and those stores returned to baseline after a one month washout [8]. Two things follow. Body glutathione status is genuinely modifiable, and it does not stay modified once support stops.

The broadest evidence comes from a randomised clinical trial in older adults using glycine and N-acetylcysteine to raise glutathione synthesis. Over 16 weeks, the intervention corrected glutathione deficiency and improved measures of oxidative stress, mitochondrial function, inflammation, and physical function [9]. Studies suggest, in other words, that restoring glutathione capacity in an ageing body may support several systems that tend to decline together, rather than acting on one organ in isolation.

None of this makes glutathione a treatment for liver disease, and nobody should read it that way. It describes a plausible mechanism with early human data attached.

The Inputs That Move the Number Most

If your ALT is drifting, the interventions with the strongest evidence behind them are unglamorous and they work.

Weight and waist circumference come first. Losing five to seven percent of body weight reliably reduces liver fat, and larger reductions do more. Second, alcohol, where the honest accounting is usually less flattering than the remembered version. Third, the composition of what you eat, with liquid fructose and heavily processed food carrying disproportionate weight. Fourth, training. Both aerobic work and resistance work reduce liver fat to a degree that is partly independent of weight loss, which is useful information if the scale is stubborn. Coffee, oddly, has consistently favourable associations with liver enzymes across large cohorts.

Then review your medicine cabinet with a clinician, including every supplement, and retest in three to six months rather than three weeks. Liver enzymes move on a timescale of months.

Where Clinical Support Fits

Some people, having handled the fundamentals honestly, want to address the antioxidant side of the equation as well. That is the category RenuviaRX operates in: physician-supervised injectable therapies, including glutathione injections starting at $109 per month, compounded by a licensed pharmacy and prescribed only after a medical review rather than sold off a shelf. Injectable delivery exists in part because of the absorption ceiling the oral supplementation trial documented [8].

It is worth being direct about the order of operations. No injection offsets a nightly bottle of wine or a waistline trending in the wrong direction, and patients who report the clearest changes are usually the ones who fixed the basics first. Cellular support is a layer on top of the fundamentals, not a substitute for them, and a raised ALT should always be evaluated by a clinician rather than self-managed.

One Number, Read Over Time

A slightly high ALT is not a verdict. It is closer to a smoke detector with a sensitive setting, and the right response is neither panic nor dismissal but a second look, a proper workup, and attention to the trend over the following year.

What makes this particular number worth watching is that it usually moves before anything else does. Fatty liver is largely reversible in its early stages, and the window in which lifestyle change does the most good tends to open long before any symptom appears. If you are curious whether physician-supervised cellular support belongs alongside those changes, a short medical questionnaire at questionnaire.renuviarx.com is a reasonable place to begin that conversation.

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.

References

1. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology. 2017;112(1):18-35. https://doi.org/10.1038/ajg.2016.517

2. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Annals of Internal Medicine. 2002;137(1):1-10. https://doi.org/10.7326/0003-4819-137-1-200207020-00006

3. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. https://doi.org/10.1097/HEP.0000000000000004

4. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine. 2012;52(1):59-69. https://doi.org/10.1016/j.freeradbiomed.2011.10.003

5. Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione: hepatocellular survival-death switch. Journal of Gastroenterology and Hepatology. 2006;21 Suppl 3:S3-S6. https://doi.org/10.1111/j.1440-1746.2006.04570.x

6. Sekhar RV, Patel SG, Guthikonda AP, et al. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. American Journal of Clinical Nutrition. 2011;94(3):847-853. https://doi.org/10.3945/ajcn.110.003483

7. Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterology. 2017;17(1):96. https://doi.org/10.1186/s12876-017-0652-3

8. Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 2015;54(2):251-263. https://doi.org/10.1007/s00394-014-0706-z

9. Kumar P, Liu C, Suliburk J, et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. Journals of Gerontology Series A. 2023;78(1):75-89. https://doi.org/10.1093/gerona/glac135